Preliminary results of Phase 1 scientific trials show that Bharat Biotech-ICMR’s coronavirus vaccine ‘Covaxin’ is protected to make use of, principal investigators conducting the trials instructed ET. “The vaccine is safe. We have not observed any adverse events in any of the volunteers at our site,” Savita Verma, principal investigator, who is main the trial at PGI Rohtak, stated.
Covaxin is being examined on 375 volunteers who’ve enrolled at 12 websites in India. Two doses of the vaccine are being administered to every volunteer.
“As of now we know that it is safe. The second step is to know how effective the vaccine is for which we have started collecting the samples,” Verma stated. It is anticipated that the Phase I will come to a end by August finish.